Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Complement factors C3a and C5a mimick a proinflammatory microenvironment and increase HBV IGRA sensitivity.

Bröker K, Terzenbach R, Bentzien F, Lüth S, Dammermann W.

J Transl Med. 2019 Jan 3;17(1):6. doi: 10.1186/s12967-018-1752-8.

2.

CpG oligonucleotides increase HBV-specific cytokine responses in whole blood and enhance cytokine release assay sensitivity.

Dammermann W, Dornbrack J, Bröker K, Bentzien F, Lüth S.

J Virol Methods. 2017 Oct;248:195-201. doi: 10.1016/j.jviromet.2017.07.011. Epub 2017 Jul 21.

PMID:
28739303
3.

Development of a novel IGRA assay to test T cell responsiveness to HBV antigens in whole blood of chronic Hepatitis B patients.

Dammermann W, Bentzien F, Stiel EM, Kühne C, Ullrich S, Schulze Zur Wiesch J, Lüth S.

J Transl Med. 2015 May 13;13:157. doi: 10.1186/s12967-015-0513-1.

4.

The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.

Foster P, Yamaguchi K, Hsu PP, Qian F, Du X, Wu J, Won KA, Yu P, Jaeger CT, Zhang W, Marlowe CK, Keast P, Abulafia W, Chen J, Young J, Plonowski A, Yakes FM, Chu F, Engell K, Bentzien F, Lam ST, Dale S, Yturralde O, Matthews DJ, Lamb P, Laird AD.

Mol Cancer Ther. 2015 Apr;14(4):931-40. doi: 10.1158/1535-7163.MCT-14-0833. Epub 2015 Jan 30.

5.

CMV specific cytokine release assay in whole blood is optimized by combining synthetic CMV peptides and toll like receptor agonists.

Dammermann W, Bochmann D, Bentzien F, Komorowski L, Steinhagen K, Ullrich S, van Lunzen J, Lüth S.

J Immunol Methods. 2014 Dec 1;414:82-90. doi: 10.1016/j.jim.2014.10.011. Epub 2014 Oct 30.

PMID:
25450001
6.

Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma.

Papadopoulos KP, Egile C, Ruiz-Soto R, Jiang J, Shi W, Bentzien F, Rasco D, Abrisqueta P, Vose JM, Tabernero J.

Leuk Lymphoma. 2015 Jun;56(6):1763-70. doi: 10.3109/10428194.2014.974040. Epub 2014 Nov 19.

PMID:
25300944
7.

Overexpression of Gremlin-1 in patients with Loeys-Dietz syndrome: implications on pathophysiology and early disease detection.

Wellbrock J, Sheikhzadeh S, Oliveira-Ferrer L, Stamm H, Hillebrand M, Keyser B, Klokow M, Vohwinkel G, Bonk V, Otto B, Streichert T, Balabanov S, Hagel C, Rybczynski M, Bentzien F, Bokemeyer C, von Kodolitsch Y, Fiedler W.

PLoS One. 2014 Aug 12;9(8):e104742. doi: 10.1371/journal.pone.0104742. eCollection 2014.

8.

Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.

Yu P, Laird AD, Du X, Wu J, Won KA, Yamaguchi K, Hsu PP, Qian F, Jaeger CT, Zhang W, Buhr CA, Shen P, Abulafia W, Chen J, Young J, Plonowski A, Yakes FM, Chu F, Lee M, Bentzien F, Lam ST, Dale S, Matthews DJ, Lamb P, Foster P.

Mol Cancer Ther. 2014 May;13(5):1078-91. doi: 10.1158/1535-7163.MCT-13-0709. Epub 2014 Mar 14.

9.

Toll like receptor 2 agonists lipoteichoic acid and peptidoglycan are able to enhance antigen specific IFNγ release in whole blood during recall antigen responses.

Dammermann W, Wollenberg L, Bentzien F, Lohse A, Lüth S.

J Immunol Methods. 2013 Oct 31;396(1-2):107-15. doi: 10.1016/j.jim.2013.08.004. Epub 2013 Aug 15.

PMID:
23954282
10.

Proinflammatory stimuli induce galectin-9 in human mesenchymal stromal cells to suppress T-cell proliferation.

Gieseke F, Kruchen A, Tzaribachev N, Bentzien F, Dominici M, Müller I.

Eur J Immunol. 2013 Oct;43(10):2741-9. doi: 10.1002/eji.201343335. Epub 2013 Jul 23.

11.

In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.

Bentzien F, Zuzow M, Heald N, Gibson A, Shi Y, Goon L, Yu P, Engst S, Zhang W, Huang D, Zhao L, Vysotskaia V, Chu F, Bautista R, Cancilla B, Lamb P, Joly AH, Yakes FM.

Thyroid. 2013 Dec;23(12):1569-77. doi: 10.1089/thy.2013.0137. Epub 2013 Sep 17.

12.

The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.

Kim MH, Tsuhako AL, Co EW, Aftab DT, Bentzien F, Chen J, Cheng W, Engst S, Goon L, Klein RR, Le DT, Mac M, Parks JJ, Qian F, Rodriquez M, Stout TJ, Till JH, Won KA, Wu X, Yakes FM, Yu P, Zhang W, Zhao Y, Lamb P, Nuss JM, Xu W.

Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85. doi: 10.1016/j.bmcl.2012.06.029. Epub 2012 Jun 16.

PMID:
22765894
13.

Discovery and characterization of an inhibitor of glucosylceramide synthase.

Richards S, Larson CJ, Koltun ES, Hanel A, Chan V, Nachtigall J, Harrison A, Aay N, Du H, Arcalas A, Galan A, Zhang J, Zhang W, Won KA, Tam D, Qian F, Wang T, Finn P, Ogilvie K, Rosen J, Aoyama R, Plonowski A, Cancilla B, Bentzien F, Yakes M, Mohan R, Lamb P, Nuss J, Kearney P.

J Med Chem. 2012 May 10;55(9):4322-35. doi: 10.1021/jm300122u. Epub 2012 Apr 19.

PMID:
22497444
14.

Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.

Ibrahim MA, Johnson HW, Jeong JW, Lewis GL, Shi X, Noguchi RT, Williams M, Leahy JW, Nuss JM, Woolfrey J, Banica M, Bentzien F, Chou YC, Gibson A, Heald N, Lamb P, Mattheakis L, Matthews D, Shipway A, Wu X, Zhang W, Zhou S, Shankar G.

J Med Chem. 2012 Feb 9;55(3):1368-81. doi: 10.1021/jm201533b. Epub 2012 Jan 24.

PMID:
22214363
15.

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.

Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH.

Mol Cancer Ther. 2011 Dec;10(12):2298-308. doi: 10.1158/1535-7163.MCT-11-0264. Epub 2011 Sep 16.

16.

KIF5B and KIF3A/KIF3B kinesins drive MT1-MMP surface exposure, CD44 shedding, and extracellular matrix degradation in primary macrophages.

Wiesner C, Faix J, Himmel M, Bentzien F, Linder S.

Blood. 2010 Sep 2;116(9):1559-69. doi: 10.1182/blood-2009-12-257089. Epub 2010 May 26.

17.

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.

Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed J, Yakes FM, Bentzien F, Xu W, Zaks T, Wooster R, Greshock J, Joly AH.

Cancer Res. 2009 Oct 15;69(20):8009-16. doi: 10.1158/0008-5472.CAN-08-4889. Epub 2009 Oct 6.

18.

Autologous blood donor screening indicated a lower prevalence of viral hepatitis in East vs West Germany: epidemiological benefit from established health resources.

Wiegand J, Luz B, Mengelkamp AK, Moog R, Koscielny J, Halm-Heinrich I, Susemihl C, Bentzien F, Diekmann J, Wernet D, Karger R, Angert K, Schmitt-Thomssen A, Kiefel V, Lutter K, Hesse R, Kätzel R, Opitz A, Luhm J, Barz D, Leib U, Matthes G, Tillmann HL.

J Viral Hepat. 2009 Oct;16(10):743-8. doi: 10.1111/j.1365-2893.2009.01132.x. Epub 2009 May 26.

PMID:
19486277
19.

Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.

Gendreau SB, Ventura R, Keast P, Laird AD, Yakes FM, Zhang W, Bentzien F, Cancilla B, Lutman J, Chu F, Jackman L, Shi Y, Yu P, Wang J, Aftab DT, Jaeger CT, Meyer SM, De Costa A, Engell K, Chen J, Martini JF, Joly AH.

Clin Cancer Res. 2007 Jun 15;13(12):3713-23.

20.

Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice.

Pan H, Nguyen NQ, Yoshida H, Bentzien F, Shaw LC, Rentier-Delrue F, Martial JA, Weiner R, Struman I, Grant MB.

Invest Ophthalmol Vis Sci. 2004 Jul;45(7):2413-9.

PMID:
15223825
21.

Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice.

Bentzien F, Struman I, Martini JF, Martial J, Weiner R.

Cancer Res. 2001 Oct 1;61(19):7356-62.

22.

Nuclear peroxisome proliferator-activated receptors alpha and gamma have opposing effects on monocyte chemotaxis in endometriosis.

Hornung D, Waite LL, Ricke EA, Bentzien F, Wallwiener D, Taylor RN.

J Clin Endocrinol Metab. 2001 Jul;86(7):3108-14.

PMID:
11443174
23.

Chemokine bioactivity of RANTES in endometriotic and normal endometrial stromal cells and peritoneal fluid.

Hornung D, Bentzien F, Wallwiener D, Kiesel L, Taylor RN.

Mol Hum Reprod. 2001 Feb;7(2):163-8.

PMID:
11160842
24.

[Mechanical autotransfusion procedures. The effect cytokines and leukocytes on washed erythrocyte concentrate].

Bentzien F, Brand JM, Röhrs E, Munkel H, Schmucker P.

Anaesthesist. 2000 Jun;49(6):505-10. German.

PMID:
10928252
25.

Induction of an angiogenic phenotype in endometriotic stromal cell cultures by interleukin-1beta.

Lebovic DI, Bentzien F, Chao VA, Garrett EN, Meng YG, Taylor RN.

Mol Hum Reprod. 2000 Mar;6(3):269-75.

PMID:
10694276
26.

Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis.

Struman I, Bentzien F, Lee H, Mainfroid V, D'Angelo G, Goffin V, Weiner RI, Martial JA.

Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1246-51.

27.

Premature luteinization in controlled ovarian hyperstimulation has no adverse effect on oocyte and embryo quality.

Hofmann GE, Bentzien F, Bergh PA, Garrisi GJ, Williams MC, Guzman I, Navot D.

Fertil Steril. 1993 Oct;60(4):675-9.

PMID:
8405524

Supplemental Content

Loading ...
Support Center